论文部分内容阅读
目的:探讨甲状旁腺功能亢进症(HPT)患者行99Tcm-MIBI与99TcmO4-联合显像对HPT病变的定位诊断价值。方法:原发性HPT患者36例,对照组10例为甲状腺疾病患者。99Tcm-MIBI注射后15min行早期相甲状旁腺显像,2h后行延迟显像。相隔24h后加做99TcmO4-甲状腺显像,对两种图像进行对比分析、视觉相减及图像判断。结果:36例HPT患者99Tcm-MIBI/99TcmO4-联合显像在甲旁腺部位或其邻近部位出现局限性核素明显增浓的阳性结果34例,假阴性结果2例,阳性率为94.44%;36例甲旁亢患者单行99Tcm-MIBI显像检出阳性结果12例,假阴性结果4例,可疑阳性结果20例,阳性率88.89%(其中55.56%为可疑阳性)。10例对照组单行99Tcm-MIBI显像出现假阳性结果3例,可疑假阳性结果1例,加做99TcmO4-显像后,对照组无假阳性结果。结论:99Tcm-MIBI/99TcmO4-联合显像可提高HPT病变诊断的阳性率,减少假阳性结果的发生,对单行99Tcm-MIBI显像出现可疑阳性结果者,联合显像有利于结果的准确判断,对甲状旁腺腺瘤的诊断与定位诊断有重要价值。
Objective: To investigate the value of 99Tcm-MIBI and 99TcmO4-combined imaging in the diagnosis of HPT in patients with hyperparathyroidism (HPT). Methods: Thirty-six patients with primary HPT and 10 patients with thyroid disease were included in the control group. Early phase parathyroid imaging was performed 15 min after injection of 99Tcm-MIBI, and delayed imaging was performed 2h later. 99TcmO4-thyroid imaging was performed 24h later, and the two images were compared, visual subtraction and image judgment. Results: Thirty-four cases of 99Tcm-MIBI / 99TcmO4-combined imaging showed focal nontumorigenicity in the parathyroid gland or its adjacent area, and the false negative results were found in 2 cases (94.44%). In 36 cases of paracacia, 99 cases of single-line 99Tcm-MIBI imaging showed positive results in 12 cases, false negative results in 4 cases and suspicious positive results in 20 cases, the positive rate was 88.89% (55.56% suspicious positive). There were 3 false-positive results in 99Tcm-MIBI imaging and 10 false-positive results in 10 patients in control group. No false-positive results were found in control group after 99TcmO4-imaging. Conclusion: 99Tcm-MIBI / 99TcmO4-combined imaging can improve the positive rate of diagnosis of HPT lesions and reduce the incidence of false-positive results. For single 99Tcm-MIBI imaging suspicious positive results, combined imaging is conducive to the accurate judgment of the results, The diagnosis and localization of parathyroid adenoma have important value.